The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as second-line treatment for advanced pancreatic adenocarcinoma: A real-world analysis.
 
Shun Tezuka
No Relationships to Disclose
 
Makoto Ueno
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Nipro Corporation; Nipro Corporation; Nipro Corporation; Nipro Corporation; Shire; Shire; Shire; Shire; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma; Teijin Pharma; Teijin Pharma; Teijin Pharma; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
Consulting or Advisory Role - Shire; Shire; Shire; Shire
Research Funding - ASLAN Pharmaceuticals (Inst); ASLAN Pharmaceuticals (Inst); ASLAN Pharmaceuticals (Inst); ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); NanoCarrier (Inst); NanoCarrier (Inst); NanoCarrier (Inst); NanoCarrier (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Shire (Inst); Shire (Inst); Shire (Inst); Shire (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst)
 
Satoshi Kobayashi
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Boston Scientific; Boston Scientific; Boston Scientific; Boston Scientific; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Eisai; Eisai; Eisai; Eisai; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Nippon Kayaku; Nippon Kayaku; Nippon Kayaku; Nippon Kayaku; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma; Teijin Pharma; Teijin Pharma; Teijin Pharma
Speakers' Bureau - Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); BeiGene (Inst); BeiGene (Inst); BeiGene (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takara Bio (Inst); Takara Bio (Inst); Takara Bio (Inst); Takara Bio (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst)
 
Manabu Morimoto
No Relationships to Disclose
 
Shuhei Nagashima
No Relationships to Disclose
 
Yusuke Sano
No Relationships to Disclose
 
Hiroyuki Asama
No Relationships to Disclose
 
Kuniyuki Kawano
No Relationships to Disclose
 
Satoshi Tanaka
No Relationships to Disclose
 
Taito Fukushima
No Relationships to Disclose